Effectiveness of stop-smoking medications: findings from the International Tobacco Control (ITC) Four Country Survey

Grants

Funding Acknowledgements

K. Michael Cummings has served as a paid consultant on smoking cessation to Pfizer and Novartis, has received payment from Pfizer and GlaxoSmithKline for lectures on smoking cessation to health professionals, and has served as a paid expert witness in litigation against the tobacco industry. All other authors declare no conflicts of interest.We would like to thank Timea Partos and Hua-Hie Yong of The Cancer Council Victoria for their input regarding evaluation of quit attempt recall. We are also grateful to the anonymous reviewers who provided insightful feedback on a previous version of this paper. The major funders of the ITC Four Country Survey are: US National Cancer Institute (P50 CA111326, P01 CA138389, R01 CA100362), Canadian Institutes of Health Research (57897, 79551, and 115016), National Health and Medical Research Council of Australia (265903, 450110, and 1005922), Cancer Research UK (C312/A3726, C312/A6465 and C312/A11039), the Robert Wood Johnson Foundation (045734) and the Canadian Tobacco Control Research Initiative (014578), with additional support from the Propel Centre for Population Health Impact, the Ontario Institute for Cancer Research and the Canadian Cancer Society Research Institute. None of the sponsors played any direct role in the design or conduct of the study, in the collection, management, analysis or interpretation of the data, in the preparation of the manuscript, or in the decision to submit the manuscript for publication.